Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198139 | 0.96 | RXRA (0.49) | MAPTRXRARXRBFFAR4FFAR1 | |
| SCHEMBL4188685 | 0.95 | RXRA (0.47) | MAPTRXRARXRBMTNR1AMTNR1B | |
| SCHEMBL4184755 | 0.94 | RXRA (0.48) | RXRARXRBMTNR1AMTNR1BHTR1D | |
| SCHEMBL11957216 | 0.94 | MTNR1A (0.46) | LMNAMAPK1L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL4197511 | 0.94 | MAPT (0.50) | MAPTLMNAMTNR1AMTNR1B | |
| SCHEMBL4188595 | 0.94 | MAPT (0.50) | MAPTLMNAMTNR1AMTNR1B | |
| SCHEMBL4197201 | 0.94 | MAPT (0.47) | MAPTLMNAMTNR1AMTNR1B | |
| SCHEMBL4199988 | 0.90 | ACACB (0.45) | MAPTLMNAACACBACACAMTNR1A | |
| SCHEMBL13383397 | 0.89 | MAPT (0.46) | MAPTLMNA | |
| SCHEMBL4204184 | 0.89 | MAPT (0.46) | MAPTLMNAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627867-B1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-7534909-B2 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1627867-A1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | METTL14, PAM, TAS2R41 | MAPT 2073/4885RXRA 360/4885RXRB 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.